---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-23-000062"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:20:26.214527+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q2 net loss $1.16B on investment swings; lowers FY2023 outlook on softer biopharma demand

## Summary
- Net sales $681.1M, down 1.4% (0.3% currency-neutral); ex-COVID revenue up 4.6% currency-neutral.
- Life Science segment sales $300.2M (-6.9%); ex-COVID growth 4.5% driven by ddPCR/qPCR.
- Clinical Diagnostics sales $380.1M (+3.3%); ex-COVID growth 4.8% on diagnostic systems and quality control.
- Operating income $89.6M vs $122.9M; net loss $1,162.3M ($39.59/sh) primarily from Sartorius AG fair value changes.
- CEO lowers FY2023 expectations due to softer demand from large biopharma and persistent early-stage biotech weakness.

## SEC filing metadata
- accession: 0000012208-23-000062
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220823000062/0000012208-23-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220823000062/bio-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-23-000062
- JSON: https://secwatch.observer/filing/0000012208-23-000062.json
- Plain text: https://secwatch.observer/filing/0000012208-23-000062.txt

## Key facts
- Earnings Releases
  BIO-RAD LABORATORIES, INC. reported the second quarter ended June 30, 2023 results: revenue $681.1 million, net income $1,162.3 million, EPS $39.59 per share. Guidance reaffirmed.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $681.1 million
  - Net income: $1,162.3 million
  - EPS: $39.59 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $691.1 million reported for the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/12208/000001220823000062/0000012208-23-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.